Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INM with free AI briefings, catalyst countdowns, and dilution alerts.

INM · InMed Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1M Cash on Hand
1.6mo Cash Runway
Follow INM by email Get an email when INM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INM, unsubscribe in one click. Privacy

📣 What INM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
INM-755 (cannabinol) cream Epidermolysis Bullosa Simplex Phase 2 · NCT04908215 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INM holds $1.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations, an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INM files for a raise →

👥 Who Owns INM

Insiders 100% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Fairmount Funds Management LLC
10% owner
Insider 10,555,507 192.14% 2026-11-06
Commodore Capital LP Institution (13G, 5%+) 2,977,630 54.20% 2026-11-06
Deep Track Capital, LP Institution (13G, 5%+) 2,977,478 54.20% 2026-11-06
Vivo Opportunity, LLC
10% owner
Insider 818,076 14.89% 2026-07-14
Vivo Opportunity Fund Holdings, L.P. 5%+ holder (13D) 718,444 13.08% 2026-05-19
SABBY MANAGEMENT, LLC 5%+ holder (13G) 280,138 5.10% 2025-12-31
ADAR1 Capital Management, LLC
10% owner
Insider 98,297 1.79% 2026-11-05
Julianne Bruno
Director · +37,000 options
Insider 33,442 0.61% 2026-11-06
Michelle Patricia Pernice
Director · +37,000 options
Insider 27,868 0.51% 2026-11-06

Share count 5,493,735 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full INM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.